Serum vitamin B12 levels and unsaturated vitamin B12 binding capacities were measured in 24 patients with multiple sclerosis (MS), 73 patients with other neurological disorders and 21 healthy subjects. There was no decrease in the vitamin B12 levels, however, a significant decrease in the unsaturated vitamin B12 binding capacities was observed in patients with MSwhen compared with other groups. A massive dose of methyl vitamin B12 (60 mg every day for 6 months) was administered to 6 patients with chronic progressive MS,a disease which usually had a morbid prognosis and widespread demyelination in the central nervous system. Although the motor disability did not improve clinically, the abnormalities in both the visual and brainstem auditory evoked potentials improved more frequently during the therapy than in the pre-treatment period.
Introduction
Acquired deficiency as well as inborn errors in vitamin B12 (cobalamin) metabolism are well knownto cause demyelination in the central nervous system (CNS) (1) (2) (3) . Neurologic disorders caused by vitamin B 1 2 deficiency occasionally appear even in the absence of megaloblastic anemia (4) . Thus, attention has been focused on the vitamin B 12 metabolism in multiple sclerosis patients in earlier reports, but the results have been conflicting (5) (6) (7) .
By using a sensitive assay, several recent studies in Western countries have shown that the vitamin B 12 levels are low in both the serum and cerebrospinal fluid (CSF) of patients with MS (8) (9) (10) . The coexistence of vitamin B12 deficiency in MSmay aggravate the disease or hinder the recovery from the disease. Therefore, the present study was undertaken to clarify the state of vitamin B12 metabolism in Japanese patients with MS. In addition, a massive dose of methyl vitamin B12 (methylcobalamin) was administered to patients with chronic progressive MS, which usually has a morbid prognosis (ll, 12) . We evaluated the efficacy of the drug by using multimodality evoked potentials (MEPs), because the clinical placebo effect does not affect the MEPresults (13).
Subjects and Methods

Subjects
The following 6 groups of subjects were studied for vitamin B12 metabolism; 24 patients with clinically definite MSdiagnosed according to the criteria of Schumacher et al (14) , 17 patients with HTLV-I-associated myelopathy (HAM)diagnosed by the criteria of Osameet al (15), 29 patients with degenerative neurologic disorders, such as Parkinson disease, spinocerebellar degeneration and motor neuron disease, 12 patients with peripheral neuropathy, 15 patients with muscle diseases and 21 healthy volunteers. Noneof the subjects were administered vitamin B12 at the time of drawing the blood specimen. Five of24 patients with MShad a previous history of vitamin B ]2 administration. Six patients with chronic progressive MS (5 primary progressive, 1 secondary progressive) were subjected to massive dose methyl vitamin B 12 treatment, after informed consent was obtained from all participating patients. Their clinical and electrophysiological features are summarized in Table 1 . Three of them had been placed on a chronic administration of either low dose prednisolone or azathioprine. Noneof them had low serum vitamin B12 levels at the entry of the present study.
Vitamin B12 in Multiple Sclerosis
Methods Serum vitamin B12 levels were determined by a radioimmunoassay(Ciba-Corning) and serum unsaturated vitamin B12 binding capacities were measured by a radioassay (16). Methyl vitamin B12 was orally administered at a dose of 60 mg every day for 6 months in 6 patients with chronic progressiveMS. In 3 patients (cases 1, 3 and4), 5 mg ofmethyl vitamin B 12 was injected intravenously every day for 14 days before the oral administration of the drug. Patients were examined neurologically every 2 to 4 weeks at the MSClinic in Kyushu University Hospital, and their disability status was evaluated according to the expanded disability status scale (EDSS) proposed by Kurtzke (17) . In order to evaluate the efficacy of the methyl vitamin B 12 more precisely, the patients were studied by multimodality evoked potentials (MEPs) consisting of patternreversal visual evokedpotentials (VEPs), brainstem auditory evoked potentials (BAEPs) and short-latency somatosensory evoked potentials (SEPs) following stimulation to the median nerve at the wrist, as described previously (18). MEPswere taken at the time of entry and 6 monthsafter the initiation of methyl vitamin B x 2 therapy in all patients and 3 months after the therapy in most patients. The MEPchanges were then determined for each side. When prolonged peak latency and interpeak latency became either normal or initially unevoked potentials appeared regardless of the latency, it wasjudged to be a definite improvement. On the other hand, when the normal evoked potentials disappeared or showed a prolongation of the latency (beyond the mean+3 SD of the normal subjects) at the followup studies, it was regarded as a definite deterioration. As there is uncertainty as to exactly what magnitude of latency change signifies a true change, changes in the prolonged latency beyond the intercession variability within either the normal or abnormal range were considered to be equivocal changes (13, 1 9, 20) . The Kruskal-Wallis H-test and the Chi-square test were used for the statistical analyses.
Results
Serumvitamin B12values and serum unsaturated vitamin B12 binding capacities
The serum vitamin B12 values were 629±243 (pg/ml, mean±SD) in MS, 598±293 in HAM, 6991243 in degenerative neurologic disorders, 676±326 in peripheral neuropathy, 658+210 in muscle diseases, and 590±262 in healthy subjects. There were no statistically significant differences among the 6 groups ( Fig. 1 Massive-dose methyl vitamin B12 therapy After the methyl vitamin B {2 therapy, 2 patients with MSfelt better, 1 remained stable and 3 became subjectively worse. The EDSSscores were unchanged in 4 and deteriorated mildly in 2 (Table 1) . Only one patient (case 5) objectively showed some improvement within the same EDSSscore. Whenthe evoked potential findings were compared between the pre-treatment recordings and the corresponding post-treatment recordings (6 months after the initiation of the therapy) in a total of 36 instances, 10 post-treatment recordings showed definite changes while the rest remained unchanged (no equivocal changes were observed in the present study). On the VEPs, the improvement was seen in 4 of 12 patients (33%) while deterioration was seen in 1 of 12 (8%) ( Table 2 ). The serial recordings of the VEPs of case 5 are shown in Fig. 3 as representatives. The patient showed absence of PI00 in both eyes before the treatment. During the course of the therapy, PI00 was obtained bilaterally with delayed peaks. On the BAEPs, 2 of 12 patients (17%) showed an improvement while none showed any deterioration.
On the SEPs, only 1 of 12 patients (8%) showed an improvement while 2 (17%) showed deterioration.
In order to evaluate the effects of spontaneous fluctuations in the MEPfindings, the pretreatment MEPchanges, i.e., the changes between the recordings at 2 months to 2 years prior to the initiation of the methyl vitamin B 12 therapy and those at the initiation of the therapy, were compared with the MEPchanges during the treatment (the MEPchanges between the recordings at the initiation of the therapy and those at 6 monthsafter the initiation of the therapy). Such comparisons were available in 28 recordings in the present study. In the pre-treatment periods, only 1 of28 recordings (4%) showed an improvement, 6 (21%) deterioration and 21 (75%) no change. On the other hand, during the treatment periods, 5 of 28 recordings (1 8%) showed an improvement, 3 (1 1 %) deterioration and 20 (7 1 %) no change.
The frequency of improvement tended to be higher in the treatment period than in the pre-treatment period (0.05<p<0. 1 , Chi-square test).
Discussion
The present study disclosed no decrease in serum vitamin B12levels but a significant decrease in the serum unsaturated vitamin B12 binding capacities in Japanese patients with MS. Recent studies in Western countries have revealed low vitamin B12 levels in the sera of patients with MS(9, 10). They suggested a possible disturbance in vitamin B 12 metabolism in MS.This notion was then further supported by the recent and early observations that the mild degree of macrocytosis without anemia is commonin patients with MS(21-24). However, the present study could not confirm the apparent vitamin B12 deficiency state in Japanese patients with MS. Since some of the present patients had a previous history of vitamin B 12 administration, it might have maskedthe vitamin B 12 deficiency state in these patients. Several MSpatients have been reported to have low vitamin B12 levels in the CSFor the red blood cells (RBC) in the presence of normal serum vitamin B 12 (8, 25) . Therefore, further study of the vitamin B12 levels in the CSF and RBGis necessary in the present patients.
The significance of a mild decrease of unsaturated vitamin B 12 binding capacities with normal vitamin B12 levels in Japanese patients with MSis still unclear. The transport of vitamin B12 and the unsaturated vitamin B12 binding capacities are associated with two carriers, i.e., transcobalamin II and R binder protein. The increase of plasma unsaturated R binder protein and the decrease of transcobalamin II have been reported in some patients with MSin one study (10). R binder protein has been postulated to removetoxic cobalamin analogues from the brain (26). There have been several reports showing the development of MS-like illness in the deficiency of R binder protein (26, 27) . On the other hand, the deficiency of transcobalamin II causes megaloblastic anemia (28). Although a further characterization of the decrease in serumunsaturated vitamin B12 binding capacities in our patients with MSis necessary, a disturbance of vitamin B 12 metabolism in MSmay be suggested. Alternatively, it may indicate the possibility of the previous administration of vitamin B12 in these patients. The cause of vitamin B12 deficiency in MSis unknown. Someauthors claim a possible association between MSand pernicious anemia, because both conditions are considered to have an autoimmune pathogenesis (24, 29). On the other hand, Prineas et al (30) revealed that remyelination frequently ensues following the destruction of myelin in the CNSof patients with MS. Thus, recurrent myelin repair in MSmay relatively increase the demand for vitamin B12 (10, 29). Weand others showed that patients with chronic progressive MShave significantly more demyelinating lesions than those with relapsing remitting MSon brain magnetic resonance imaging (MRI) ( 1 8, 31) . The presence of widespread demyelination in chronic progressive MShas also been confirmed pathologically (32, 33) . Therefore, the demand for vitamin B12 may be higher in patients with chronic progressive MSthan in those with relapsing-remitting MS.
In the present patients, motor disability did not improve clinically after the administration of massive doses of methyl vitamin B12. However, the MEPabnormalities reflecting the demyelinating lesions in the afferent pathways improved more frequently in the treatment period than in the pre-treatment period. Such a clinico-electrophysiologic discrepancy was also noted in the previous studies (13, 20) . Serial MEPstudies in chronic progressive MSare rare. Anderson et al (13) reported that evoked potential changes occurred in 23% of the instances at a 3-month interval in chronic progressive and stable MS. The figure was comparable to ours (about 30%overall changes). Importantly, the rates of improvementand deterioration were similar in their study (13), but in our study there was more than a two-fold difference between the two rates. Our patients showed a tendency to improve in VEPs and BAEPsbut not in SEPs during the therapy, which may be related to the more severe involvement of the spinal cord than other parts of the CNSin chronic progressive MS (1 8 
